STOCK TITAN

GLAUKOS (GKOS) SEC Filings, Mar 17-25, 2026

GKOS NYSE

Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.

The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.

Rhea-AI Summary

Glaukos Corp Senior Vice President and Chief Financial Officer Alex R. Thurman reported recent stock transactions. On March 24, he sold 1,521 shares of common stock in an open-market trade at an average price of $105.24 per share under a pre-arranged Rule 10b5-1 trading plan adopted on December 15, 2025. Following these transactions, he directly holds 44,478 shares of common stock, and his holdings also include restricted stock units that have not yet vested or been delivered, as described in the footnotes. Additional dispositions of 2,020 shares on March 24 and 1,230 shares on March 23 were shares withheld by the company to cover tax obligations upon vesting of restricted stock units granted in 2023 and 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp president and COO Joseph E. Gilliam reported routine share dispositions tied to tax withholding, not open-market sales. On March 23 and 24, 2026, a total of 15,118 shares of common stock were withheld by the company to cover his tax obligations upon restricted stock unit vesting. Following these transactions, he continues to hold 72,540 shares of common stock directly. Footnotes indicate his holdings also include unvested restricted stock units from prior grants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
insider
-
Rhea-AI Summary

Alex Thurman, an officer of GLAUKOS Corp. (GKOS), reported a proposed sale of 2,511 common shares, with an aggregate market value of $267,321.06 and an approximate sale date of March 25, 2026, through Fidelity Brokerage Services LLC. The reported Rule 10b5-1 plan adoption or instruction date is December 15, 2025.

Thurman acquired 2,511 shares through restricted-stock vesting on March 24, 2026. The reported sales during the prior three months include 1,521 shares sold on March 24 for gross proceeds of $160,070.04 and 625 shares sold on March 17 for gross proceeds of $61,968.75.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.15%
Tags
other
Rhea-AI Summary

GLAUKOS Corp (GKOS) officer Alex R. Thurman gave notice of a proposed sale of 1,521 common shares, with an aggregate market value of $160,070.04 and an approximate sale date of March 24, 2026. The notice lists 1,521 shares acquired from the issuer through restricted stock vesting on March 22, 2026. It also reports that Thurman sold 625 common shares on March 17, 2026, for gross proceeds of $61,968.75. The notice lists December 15, 2025, as the date of plan adoption or giving of instruction, if relying on Rule 10b5-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.51%
Tags
other
-
Rhea-AI Summary

Glaukos Corp chief development officer Tomas Navratil reported a combination of tax withholding and open-market sales of company stock. On March 16, 2026, 958 shares of common stock were withheld to cover tax obligations tied to the vesting of previously granted restricted stock units.

On the same date, he sold a total of 1,031 common shares in open-market transactions at weighted average prices of $97.33, $98.21, and $99.05 per share, under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly beneficially owns 73,631 shares of Glaukos common stock, including 35,687 restricted stock units that have not yet vested or been delivered.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp senior vice president and chief financial officer Alex R. Thurman reported two recent stock transactions. On March 17, 2026, he executed an open‑market sale of 625 shares of common stock at $99.15 per share. On March 16, 2026, 614 shares were disposed of to cover tax withholding obligations tied to vesting of restricted stock units granted on March 14, 2024, which is a non‑market event. After these transactions, he directly held 49,249 shares of common stock, including 12,512 restricted stock units that have not yet vested or been delivered and 167 stock units acquired through the employee stock purchase plan. The sale was carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on December 15, 2025, indicating it was scheduled in advance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
insider
Rhea-AI Summary

GLAUKOS Corp’s President & COO Joseph E. Gilliam reported a routine tax-related share disposition. On the vesting of previously granted restricted stock units, 1,189 shares of common stock were withheld by the company to cover his tax obligations.

After this withholding, Gilliam directly holds 87,658 shares of GLAUKOS common stock, which the disclosure states includes 53,986 restricted stock units that are granted but not yet vested or delivered. This event reflects compensation and tax mechanics rather than an open‑market stock sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
insider
-
Form 4
Rhea-AI Summary

GLAUKOS Corp chairman and CEO Thomas William Burns reported a routine tax-related share disposition. On March 16, 2,801 shares of common stock were withheld by the company at $98.94 per share to satisfy tax obligations tied to previously granted restricted stock units.

After this withholding, Burns directly holds 242,451 common shares and also has indirect holdings through several family-related trusts. The disclosure notes 64,610 restricted stock units that have not yet vested or been delivered, indicating additional potential future share delivery subject to vesting conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp President & COO Joseph E. Gilliam reported a routine tax-related share disposition. On March 13, 2026, 2,462 shares of common stock at $97.02 per share were withheld by the company to satisfy his tax withholding obligations upon vesting of previously granted restricted stock units.

After this withholding, Gilliam directly holds 88,847 common shares. A footnote also states that his holdings include 56,132 restricted stock units that have not yet vested or been delivered, highlighting a substantial ongoing equity-based compensation position. This event reflects tax settlement mechanics rather than an open-market sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
insider
Rhea-AI Summary

Glaukos Corp chief development officer Tomas Navratil reported a tax-related share disposition. On March 13, 2026, 1,074 shares of common stock were withheld at $97.02 per share to satisfy tax withholding obligations tied to vesting restricted stock units.

After this tax-withholding disposition, Navratil directly holds 75,620 shares of common stock, which includes 38,456 restricted stock units that have not yet vested or been delivered.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
insider

FAQ

How many GLAUKOS (GKOS) SEC filings are available on StockTitan?

StockTitan tracks 174 SEC filings for GLAUKOS (GKOS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GLAUKOS (GKOS)?

The most recent SEC filing for GLAUKOS (GKOS) was filed on November 20, 2026.